• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?

作者信息

Bastard Mathieu, Guglielmetti Lorenzo, Huerga Helena, Hayrapetyan Armen, Khachatryan Naira, Yegiazaryan Lusine, Faqirzai Jamil, Hovhannisyan Lana, Varaine Francis, Hewison Catherine

机构信息

1 Epicentre Paris, France.

2 Médecins Sans Frontières Paris, France.

出版信息

Am J Respir Crit Care Med. 2018 Nov 1;198(9):1228-1231. doi: 10.1164/rccm.201801-0019LE.

DOI:10.1164/rccm.201801-0019LE
PMID:29969054
Abstract
摘要

相似文献

1
Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?贝达喹啉及其他用于耐氟喹诺酮类多药耐药结核病的 repurposed 药物：它们的效果究竟好多少？ （注：“repurposed drugs”直译为“重新利用的药物”，这里可理解为“其他有新用途的药物”，但在专业语境下可能有更准确的医学术语对应，因未提供更多背景信息暂这样译）
Am J Respir Crit Care Med. 2018 Nov 1;198(9):1228-1231. doi: 10.1164/rccm.201801-0019LE.
2
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?贝达喹啉在治疗耐多药结核病方面与氟喹诺酮类药物一样有效吗？
Eur Respir J. 2016 Aug;48(2):582-5. doi: 10.1183/13993003.00411-2016. Epub 2016 Jun 23.
3
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.亚美尼亚、印度和南非采用贝达喹啉与德拉马尼联合治疗耐多药结核病患者的早期安全性和疗效：一项回顾性队列研究。
Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13.
4
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.使用贝达喹啉和地拉曼尼联合治疗耐氟喹诺酮类多药耐药结核病：韩国一项全国性队列研究
Eur Respir J. 2021 Mar 4;57(3). doi: 10.1183/13993003.03026-2020. Print 2021 Mar.
5
The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.使用贝达喹啉治疗耐多药结核病和终末期肾病患者：一例报告。
Int J Infect Dis. 2018 Nov;76:88-90. doi: 10.1016/j.ijid.2018.09.009. Epub 2018 Sep 19.
6
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.贝达喹啉在儿童和青少年耐多药结核病中的超说明书使用。
Emerg Infect Dis. 2017 Oct;23(10):1711-3. doi: 10.3201/eid2310.170303. Epub 2017 Oct 17.
7
Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.贝达喹啉可作为氟喹诺酮类药物耐药利福平耐药结核病标准化治疗方案中的核心药物。
Eur Respir J. 2022 Mar 24;59(3). doi: 10.1183/13993003.02124-2021. Print 2022 Mar.
8
Multidrug-resistant tuberculosis and bedaquiline.耐多药结核病与贝达喹啉
N Engl J Med. 2014 Dec 18;371(25):2435-6. doi: 10.1056/NEJMc1412235.
9
Multidrug-resistant tuberculosis and bedaquiline.耐多药结核病与贝达喹啉
N Engl J Med. 2014 Dec 18;371(25):2436. doi: 10.1056/NEJMc1412235.
10
Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.对抗耐药结核病：贝达喹啉的意外益处
Int J Tuberc Lung Dis. 2017 Jan 1;21(1):4-5. doi: 10.5588/ijtld.16.0768.

引用本文的文献

1
Effect of Bdq-Containing Regimen and Molecular Detection of Bdq Resistance among Pre-XDR-TB Patients with Unfavorable Outcomes.含贝达喹啉方案的疗效及预广泛耐药结核病患者中贝达喹啉耐药的分子检测与不良预后
Int J Gen Med. 2025 Aug 14;18:4469-4480. doi: 10.2147/IJGM.S538660. eCollection 2025.
2
Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TB.用于耐多药结核病的贝达喹啉、利奈唑胺、氯法齐明“核心”方案的有效性
IJTLD Open. 2025 May 12;2(5):269-275. doi: 10.5588/ijtldopen.24.0515. eCollection 2025 May.
3
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
评估氟喹诺酮类耐药（endTB-Q）的耐多药结核病联合方案中新批准的药物：一项多国随机对照试验研究方案。
Trials. 2023 Nov 30;24(1):773. doi: 10.1186/s13063-023-07701-6.
4
The Efficacy and Safety of Bedaquiline in the Treatment of Pulmonary Tuberculosis Patients: A Systematic Review and Meta-Analysis.贝达喹啉治疗肺结核患者的疗效与安全性：一项系统评价和荟萃分析
Antibiotics (Basel). 2023 Aug 31;12(9):1389. doi: 10.3390/antibiotics12091389.
5
Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.修订的结核病耐药和治疗结果定义，法国，2006-2019 年。
Emerg Infect Dis. 2022 Sep;28(9):1796-1804. doi: 10.3201/eid2809.220458.
6
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.贝达喹啉和/或德拉马尼治疗患者的文化转变。一项前瞻性多国研究。
Am J Respir Crit Care Med. 2021 Jan 1;203(1):111-119. doi: 10.1164/rccm.202001-0135OC.
7
Treatment as prevention and other interventions to reduce transmission of multidrug-resistant tuberculosis.治疗即预防和其他干预措施以减少耐多药结核病的传播。
Int J Tuberc Lung Dis. 2019 Apr 1;23(4):396-404. doi: 10.5588/ijtld.18.0276.
8
Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes.耐氟喹诺酮和广泛耐药结核病治疗效果改善
Open Forum Infect Dis. 2019 Apr 1;6(4):ofz118. doi: 10.1093/ofid/ofz118. eCollection 2019 Apr.